LXEO vs PATH · $147.7M cap vs P/E 19, rev $1.61B
Lexeo Therapeutics, Inc. Common Stock (LXEO) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Lexeo Therapeutics, Inc. Common Stock (LXEO) is a biotechnology company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
LXEO does not have a complete income-statement cache yet.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
LXEO currently screens at market cap $147.7M. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the LXEO and PATH stock pages for the full models.
Not investment advice.